CH505 TF mRNA-gp160

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV Infections

Phase 1

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

Active, not recruitingNCT06557785

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2024-11-25End: 2027-03-09Updated: 2026-01-14

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

Not yet recruitingNCT07757802

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2026-09-10End: 2028-10-07Target: 54Updated: 2026-08-11